How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/unresectable-advanced-or-recurrent-malignant-pleural-mesothelioma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Unresectable advanced or recurrent malignant pleural mesothelioma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unresectable advanced or recurrent malignant pleural mesothelioma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Unresectable advanced or recurrent malignant pleural mesothelioma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Opdivo	nivolumab	Bristol-Myers Squibb	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death protein 1	2014-01-01
Yervoy	Yervoy	Bristol-Myers Squibb		Cytotoxic T-lymphocyte protein 4
Yervoy	ipilimumab	Bristol-Myers Squibb	CTLA-4-directed Blocking Antibody	Cytotoxic T-lymphocyte protein 4	2011-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 3 drugs in Unresectable advanced or recurrent malignant pleural mesothelioma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unresectable advanced or recurrent malignant pleural mesothelioma:

Cite this brief

Drug Landscape (2026). Unresectable advanced or recurrent malignant pleural mesothelioma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-advanced-or-recurrent-malignant-pleural-mesothelioma. Accessed 2026-06-10.

Unresectable advanced or recurrent malignant pleural mesothelioma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing